Skip to Main Content
Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Issues

Browse by volume
Volume 47, Issue 6
December 1, 2022
Issue Cover
Issue Editors
Stacie B. Dusetzina
Stacie B. Dusetzina
Search for other works by this author on:
This Site
Google
Jonathan Oberlander
Jonathan Oberlander
Search for other works by this author on:
This Site
Google
ISSN 0361-6878
EISSN 1527-1927
In this Issue
Search within issue

The Price of Progress: Managing Prescription Drug Spending

Articles

The Price of Progress: Managing Prescription Drug Spending
Stacie B. Dusetzina; Jonathan Oberlander
View articletitled, The Price of Progress: Managing Prescription Drug Spending
Open the PDF for in another window
The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies
Pragya Kakani; Michael Chernew; Amitabh Chandra
View articletitled, The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies
Supplementary data
Open the PDF for in another window
Trends in the Quality of Evidence Supporting FDA Drug Approvals: Results from a Literature Review
Beatrice L. Brown; Mayookha Mitra-Majumdar; Krysten Joyce; Murray Ross; Catherine Pham ...
View articletitled, Trends in the Quality of Evidence Supporting FDA Drug Approvals: Results from a Literature Review
Supplementary data
Open the PDF for in another window
Medicaid and Accelerated Approval: Spending on Drugs with and without Proven Clinical Benefits
Rachel E. Sachs; Shelley A. Jazowski; Kyle A. Gavulic; Julie M. Donohue; Stacie B. Dusetzina
View articletitled, Medicaid and Accelerated Approval: Spending on Drugs with and without Proven Clinical Benefits
Supplementary data
Open the PDF for in another window
Improving Access to High-Value, High-Cost Medicines: The Use of Subscription Models to Treat Hepatitis C Using Direct-Acting Antivirals in the United States
Samantha G. Auty; Kevin N. Griffith; Paul R. Shafer; Rebekah E. Gee; Rena M. Conti
View articletitled, Improving Access to High-Value, High-Cost Medicines: The Use of Subscription Models to Treat Hepatitis C Using Direct-Acting Antivirals in the United States
Open the PDF for in another window
Pursuing Pharmacoequity: Determinants, Drivers, and Pathways to Progress
Rohan Chalasani; Sudarshan Krishnamurthy; Katie J. Suda; Terri V. Newman; Scott W. Delaney ...
View articletitled, Pursuing Pharmacoequity: Determinants, Drivers, and Pathways to Progress
Open the PDF for in another window
Insulin Shocks
Joseph White; Nicholas Corwin
View articletitled, Insulin Shocks
Open the PDF for in another window
Assessing US Pharmaceutical Policy and Pricing Reform Legislation in Light of European Price and Cost Control Strategies
Marc A. Rodwin
View articletitled, Assessing US Pharmaceutical Policy and Pricing Reform Legislation in Light of European Price and Cost Control Strategies
Open the PDF for in another window
International Reference Pricing in the Context of US Drug Policy
Richard Frank; Rena M. Conti; Jonathan Gruber
View articletitled, International Reference Pricing in the Context of US Drug Policy
Open the PDF for in another window
Value-Based Insurance Design: Clinically Nuanced Consumer Cost Sharing to Increase the Use of High-Value Medications
Nicholas K. Smith; A. Mark Fendrick
View articletitled, Value-Based Insurance Design: Clinically Nuanced Consumer Cost Sharing to Increase the Use of High-Value Medications
Open the PDF for in another window
Industry Payments to Physicians Are Kickbacks. How Should Stakeholders Respond?
Aaron Mitchell; Ameet Sarpatwari; Peter B. Bach
View articletitled, Industry Payments to Physicians Are Kickbacks. How Should Stakeholders Respond?
Open the PDF for in another window
Reduction in Medicaid Rebates Paid by Pharmaceutical Manufacturers for Outpatient Infused, Injected, Implanted, Inhaled, or Instilled Drugs: The 5i Loophole
Sean Dickson; Nico Gabriel; Walid Gellad; Inmaculada Hernandez
View articletitled, Reduction in Medicaid Rebates Paid by Pharmaceutical Manufacturers for Outpatient Infused, Injected, Implanted, Inhaled, or Instilled Drugs: The 5i Loophole
Supplementary data
Open the PDF for in another window
Reforming the Medicare Part D Benefit Design: Financial Implications for Beneficiaries, Private Plans, Drug Manufacturers, and the Federal Government
Erin Trish; Katrina M. Kaiser; Jeanai Celestin; Geoffrey Joyce
View articletitled, Reforming the Medicare Part D Benefit Design: Financial Implications for Beneficiaries, Private Plans, Drug Manufacturers, and the Federal Government
Open the PDF for in another window
The Bayh-Dole Act at 40: Accomplishments, Challenges, and Possible Reforms
Ameet Sarpatwari; Aaron S. Kesselheim; Robert Cook-Deegan
View articletitled, The Bayh-Dole Act at 40: Accomplishments, Challenges, and Possible Reforms
Open the PDF for in another window
All Issues

Advertisement

  • Online ISSN 1527-1927
  • Print ISSN 0361-6878
  • Copyright © 2025 Duke University Press
  • Duke University Press
  • 905 W. Main St. Ste. 18-B
  • Durham, NC 27701
  • USA
  • Phone
  • (888) 651-0122
  • International
  • +1 (919) 688-5134
  • Contact
  • Contact Us
Duke University Press
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept